OC
PCRX icon

Oppenheimer & Co’s Pacira BioSciences PCRX Stock Holding History

Oppenheimer & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-34,800
Closed -$1.01M – 1355
2013
Q2 		$1.01M Buy
+34,800
New +$1.01M 0.04% 513

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Oppenheimer & Co's PCRX Position: Q3 2013 in Review

Oppenheimer & Co sold out of Pacira BioSciences (PCRX) in Q3 2013, closing a stake of 34,800 shares — an estimated $1.01M sold.

Oppenheimer & Co first reported a position in PCRX in Q2 2013 and held it in 1 quarter. The position peaked at $1.01M in Q2 2013. 130 funds tracked by Wall St. Rank hold PCRX as of Q3 2013.

  • Oppenheimer & Co reported no remaining Pacira BioSciences position as of Q3 2013 after selling out during the quarter.
  • Oppenheimer & Co sold 34,800 Pacira BioSciences shares in Q3 2013, an estimated $1.01M.
  • Oppenheimer & Co first reported a position in Pacira BioSciences in Q2 2013 and held it in 1 quarter.
  • Oppenheimer & Co's Pacira BioSciences position peaked at $1.01M in Q2 2013.
  • 130 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2013.

Based on Oppenheimer & Co's 13F filing for Q3 2013, filed 1 Nov 2013.